Sugi Predict

Sugi Predict / Compounds / SCHEMBL956608

SCHEMBL956608

SCHEMBL956608

O=C(O)c1n[nH]c2ccc(F)cc12

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PRKAG1 P54619 6/20 0.55
▸ PRKAA1 Q13131 6/20 0.55
▸ PRKAB1 Q9Y478 6/20 0.55
▸ HAO1 Q9UJM8 2/20 0.54
▸ MAP2K4 P45985 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ MAPK6 Q16659 1/20 0.50
▸ PRKAB2 O43741 5/20 0.49
▸ PRKAA2 P54646 5/20 0.49
▸ PRKAG3 Q9UGI9 5/20 0.49
▸ PRKAG2 Q9UGJ0 5/20 0.49
▸ KDM4E B2RXH2 1/20 0.46
▸ RBP4 P02753 1/20 0.46
▸ WNT1 P04628 1/20 0.45
▸ DYRK1A Q13627 1/20 0.45
▸ AHR P35869 1/20 0.45
▸ NTRK1 P04629 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HCAR2 Q8TDS4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11220634 0.89 KDM4E (0.54) PRKAG1PRKAA1PRKAB1HAO1MAP2K4
SCHEMBL15253767 0.88 RBP4 (0.46) PRKAG1PRKAA1PRKAB1MAP2K4MAPK1
SCHEMBL2816583 0.86 MAP2K4 (0.61) PRKAG1PRKAA1PRKAB1HAO1MAP2K4
SCHEMBL28575862 0.85 NTRK1 (0.58) MAP2K4MAPK1MAPK6RBP4WNT1
SCHEMBL591699 0.85 RBP4 (0.45) PRKAG1PRKAA1PRKAB1MAP2K4MAPK1
SCHEMBL30016324 0.83 HAO1 (0.48) PRKAG1PRKAA1PRKAB1HAO1MAP2K4
SCHEMBL20207316 0.81 NTRK1 (0.51) KDM4EWNT1DYRK1ANTRK1
SCHEMBL2536370 0.81 KDM4E (0.63) PRKAG1PRKAA1PRKAB1MAP2K4KDM4E
SCHEMBL1963463 0.81 PRKAG1 (0.56) PRKAG1PRKAA1PRKAB1HAO1PRKAB2
SCHEMBL4008217 0.81 PRKAG1 (0.56) PRKAG1PRKAA1PRKAB1HAO1PRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122005693-A Application of Jiaweidanzhi Xiaoyao powder or extract thereof in preparation of medicines for treating depression complicated with ulcerative colitis 河南中医药大学 2026-05-12 — — CN claimed
EP-1670787-A4 CYTOKINE INHIBITORS KEMIA INC (US) 2009-04-22 — — EP claimed
CN-1878769-A Cytokine inhibitors KEMIA INC (US) 2006-12-13 — — CN claimed
EP-1670787-A2 CYTOKINE INHIBITORS Kemia, INC. (US) 2006-06-21 — — EP claimed
US-20050107399-A1 Cytokine inhibitors KEMIA, INC. 2005-05-19 — — US claimed
WO-2005023761-A2 CYTOKINE INHIBITORS KEMIA, INC. (US) 2005-03-17 — — WO claimed
CN-122005693-A Application of Jiaweidanzhi Xiaoyao powder or extract thereof in preparation of medicines for treating depression complicated with ulcerative colitis 河南中医药大学 2026-05-12 — — CN disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
US-20260022131-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-01-22 — — US disclosed
US-12473302-B2 4-phenylpiperidines, their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-11-18 — — US disclosed
US-12128026-B2 Selective androgen receptor degrader (SARD) ligands and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2024-10-29 — — US disclosed
CN-118206489-B 1, 3-Phenylenediamine derivative with anti-tumor activity, preparation method and application 国王医学科技(山东)有限公司 2024-09-24 — — CN disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 — — US disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 — — US disclosed
US-20050107399-A1 Cytokine inhibitors KEMIA, INC. 2005-05-19 — — US disclosed
WO-2005023761-A2 CYTOKINE INHIBITORS KEMIA, INC. (US) 2005-03-17 — — WO disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 — — EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 — — US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 PRKAG1 744/4885PRKAA1 365/4885PRKAB1 741/4885
US-20050107399-A1 Cytokine inhibitors TNF, IL1RN, IL1A PRKAG1 2498/4885PRKAA1 2180/4885PRKAB1 2414/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A PRKAG1 712/4885PRKAA1 386/4885PRKAB1 664/4885
US-12473302-B2 4-phenylpiperidines, their preparation and use HTR3C, HRH4, DRD3 PRKAG1 4137/4885PRKAA1 3186/4885PRKAB1 3838/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH PRKAG1 1242/4885PRKAA1 1530/4885PRKAB1 1623/4885
US-12128026-B2 Selective androgen receptor degrader (SARD) ligands and methods of use thereof AR, AHR, BRDT PRKAG1 2437/4885PRKAA1 1008/4885PRKAB1 3054/4885
US-20260022131-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE CLN6, NR2E3, CBR3 PRKAG1 2139/4885PRKAA1 1337/4885PRKAB1 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.